

*Name of Committee:* Genes, Genomes, and Genetics Integrated Review Group, Genetics of Health and Disease Study Section.

*Date:* October 19–20, 2006.

*Time:* 9 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Watergate, 2650 Virginia Avenue, NW., Washington, DC 20037.

*Contact Person:* Cheryl M. Corsaro, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2204, MSC 7890, Bethesda, MD 20892, (301) 435–1045, [corsaroc@csr.nih.gov](mailto:corsaroc@csr.nih.gov).

*Name of Committee:* Biology of Development and Aging Integrated Review Group, International and Cooperative Projects—1 Study Section.

*Date:* October 20, 2006.

*Time:* 8 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Doubletree Hotel, 1515 Rhode Island Avenue, NW., Washington, DC 20005.

*Contact Person:* Manana Sukhareva, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3214, MSC 7808, Bethesda, MD 20892, 301–435–1116, [sukharem@csr.nih.gov](mailto:sukharem@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Community Level Health Promotion R21, R15 and R03's.

*Date:* October 20, 2006.

*Time:* 8:30 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Fungai F. Chanetsa, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3135, MSC 7770, Bethesda, MD 20892, 301–435–1262, [chanetsaf@csr.nih.gov](mailto:chanetsaf@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Stress Biomarkers as Disease Risk Factors.

*Date:* October 20, 2006.

*Time:* 8:30 a.m. to 9:30 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hotel Helix, 1430 Rhode Island Avenue, NW., Washington, DC 20005.

*Contact Person:* Luci Roberts, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3188, MSC 7848, Bethesda, MD 20892, (301) 435–0692, [roberlu@csr.nih.gov](mailto:roberlu@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Heart Development and Vascular Remodeling.

*Date:* October 20, 2006.

*Time:* 9 a.m. to 10:30 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Beacon Hotel and Corporate Quarters, 1615 Rhode Island Avenue, NW., Washington, DC 20036.

*Contact Person:* Anshumali Chaudhari, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4124,

MSC 7802, Bethesda, MD 20892, (301) 435–1210, [chaudhaa@csr.nih.gov](mailto:chaudhaa@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Collaborative Applications in Child Psychopathology.

*Date:* October 20, 2006.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037.

*Contact Person:* Jane A. Doussard-Roosevelt, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7848, Bethesda, MD 20892, (301) 435–4445, [doussarj@csr.nih.gov](mailto:doussarj@csr.nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 14, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–8094 Filed 9–21–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Intercellular Interactions Study Section, October 3, 2006, 8 a.m. to October 4, 2006, 6:30 p.m., Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814 which was published in the **Federal Register** on September 7, 2006, 71 FR 52809–52810.

The meeting will be held at The Watergate, 2650 Virginia Avenue, NW., Washington, DC 20037. The meeting dates and time remain the same. The meeting is closed to the public.

Dated: September 14, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–8095 Filed 9–21–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Option to a Co-Exclusive License: Development of Antibody-Based Therapeutics That Specifically Bind the Platelet-Derived Growth Factor Receptor Alpha (CD140A/PDGFR2/PDGFRA)

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an option to a co-exclusive commercialization license to practice the inventions embodied in any or all of (a) U.S. patents 5,468,468 (11/21/1995); 5,833,986 (11/10/1998); 5,863,739 (01/26/1999); 5,965,359 (10/12/1999); 6,228,600 (05/08/2001) and 6,660,488 (12/09/2003), (b) U.S. patent applications 07/308,282 (02/09/1989, now abandoned), 07/915,884 (7/20/1992, now abandoned), 08/439,095 (05/11/1995, pending), 10/700,249 (11/03/2003, pending) and (c) foreign applications corresponding to PCT Patent Application PCT/US90/00617 entitled "Type Alpha Platelet Derived Growth Factor Receptor Gene", published as WO 90/10013 (9/7/1990) to AstraZeneca Pharmaceuticals LP having a principal place of business in Boston, MA.

The prospective option to a co-exclusive license will have a Licensed Territory which is worldwide. The prospective option to the co-exclusive license will have a Field of Use limited to the development of compositions and methods of utilizing antibody-based products that specifically bind the alpha platelet-derived growth factor receptor ( $\alpha$ -PDGFR/CD140a/PDGFRA/PDGF2/PDGFR- $\alpha$ ), for the treatment of cancer and diagnostics specifically useful therewith. Only a single option to a co-exclusive license will be granted. This notice modifies the notice previously published at FR 69(165): 52514–15 (August 26, 2004).

**DATES:** Only written comments and/or applications for a license which are received by NIH within sixty (60) days of this notice will be considered. Comments and/or objections filed in response to the notices of January 27, 1993, February 15, 1994 and August 26, 2004 are not considered responsive to

this notice and will not be treated as objections thereto.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comment and other materials relating to the contemplated license should be directed to Susan S. Rucker, Esq., Senior Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/435-4478; fax: 301/402-0220; or e-mail: [ruckersu@mail.nih.gov](mailto:ruckersu@mail.nih.gov). A signed Confidentiality Agreement (CDA) will be required to receive copies of the patent applications not otherwise publicly available. Interested parties may obtain copies of U.S. patents and pending U.S. patent applications at <http://www.uspto.gov>. European patents and patent applications as well as other international patent documents are available at: <http://www.epoline.org>. Information on Canadian Patents is available at: <http://patents1.ic.gc.ca/>.

**SUPPLEMENTARY INFORMATION:** The patents and patent applications describe and claim compositions and methods that incorporate or are derived from the molecule known as alpha platelet-derived growth factor receptor ( $\alpha$ -PDGFR).  $\alpha$ -PDGFR is also known as CD140a/PDGFR $\alpha$ /PDGFR2/PDGFR- $\alpha$ . PDGFR- $\alpha$  is a type III receptor tyrosine kinase characterised by an extracellular domain having five IgG-like domains, a transmembrane domain and a catalytic intracellular domain. Research suggests it has autocrine and paracrine signaling capability. PDGFR $\alpha$  expression and signaling have been linked to tumorigenesis and its activity, although not always coupled with over-expression, has been implicated in a number of cancers including lung cancer, ovarian cancer, prostate cancer, glioblastoma and melanoma.

The prospective option to a co-exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective option to a co-exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (*i.e.*, a completed "Application for License to Public Health Service Inventions") in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated option to a co-exclusive

license. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 5 U.S.C. 552.

Dated: September 18, 2006.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 06-8083 Filed 9-21-06; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Office of Grants and Training, Citizens Corps; Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** DHS, Office of Grants and Training, Citizens Corps.

**ACTION:** Notice and request for comments.

**SUMMARY:** Department of Homeland Security (DHS), has submitted the following information collection to the Office of Management and Budget (OMB) for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. The submission describes the nature of the information collection, the categories of respondents, the estimated burden (*i.e.*, the time, effort and resources used by respondents to respond) and cost, and includes the actual data collection instruments DHS will use.

*Title:* Citizens Corps Individual Registration.

*OMB Number:* 1660-0078.

*Abstract:* This information collection will enable Citizens Corps to operate effectively and efficiently to regularize and coordinate activities between Citizens Corps and those groups active in education, training and coordinating volunteers in crime prevention, disaster preparedness, mitigation, public health and safety issues.

*Affected Public:* Individual citizens.

*Number of Respondents:* 20,000 per year.

*Estimated Time per Respondent:* 5 minutes.

*Estimated Total Annual Burden Hours:* 1,666.66.

*Frequency of Response:* On occasion.

*Comments:* Interested persons are invited to submit written comments on the proposed information collection to the Office of Information and Regulatory Affairs, Office of Management Budget, Attention: Nathan Lesser, Desk Officer, Department of Homeland Security/and

sent via electronic mail to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov) or faxed to (202) 395-6974. Comments must be submitted on or before October 23, 2006.

### FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the information collection should be made to Chief, Records Management, DHS, Office of Community Preparedness, Karen Marsh, 810 7th Street, NW., Washington, DC 20531, [Karen.Marsh@dhs.gov](mailto:Karen.Marsh@dhs.gov), phone number (202) 577-9820 and fax number (202) 786-9619.

Dated: September 15, 2006.

**Charlie Church,**

*Chief Information Officer, Information and Technology Division, Preparedness Directorate, Department of Homeland Security.*

[FR Doc. 06-7872 Filed 9-21-06; 8:45 am]

**BILLING CODE 4410-10-P**

## DEPARTMENT OF HOMELAND SECURITY

### Office of Grants and Training, Citizens Corps; Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** DHS, Office of Grants and Training, Citizens Corps.

**ACTION:** Notice and request for comments.

**SUMMARY:** Department of Homeland Security (DHS), has submitted the following information collection to the Office of Management and Budget (OMB) for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. The submission describes the nature of the information collection, the categories of respondents, the estimated burden (*i.e.*, the time, effort and resources used by respondents to respond) and cost, and includes the actual data collection instruments DHS will use.

*Title:* Citizens Corps Council & CERT Program Registration.

*OMB Number:* 1660-0079.

*Abstract:* This information collection will enable Citizens Corps to operate effectively and efficiently to regularize and coordinate activities between Citizens Corps and those groups active in education, training and coordinating volunteers in crime prevention, disaster preparedness, mitigation, public health and safety issues.

*Affected Public:* State and local Citizens Corps Councils and CERT Programs.

*Number of Respondents:* 500 per year.